info icon

Fetal alcohol syndrome (dysmorphic)

Q17_FETAL_ALCOHOL_SYNDR_DYSMORPHIC

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 Q86.0
  • Cause of death: ICD-10 Q86.0

2 out of 7 registries used, show all original rules.

31

4. Check minimum number of events

None

31

5. Include endpoints

None

31

6. Filter based on genotype QC (FinnGen only)

31

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
4
Special
FAS
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q86
Name in latin
Syndroma fetale alcoholicum [dysmorphicum]

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1003 434 569
Only index persons 861 385 476
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.02
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population - 6.34 6.93
Only index persons 7.11 6.83 7.34

-FinnGen-

Key figures

All Female Male
Number of individuals 31 16 15
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 12.54 9.52 15.75

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

No data available

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma
19
89
3.93
3.36
7.9
4.4
umol/l
8.8
10.8
0.53
19
80
(3022313) Gas panel - Capillary blood
6
12
5.90
2.53
2.8
11.2
—
—
—
0
0
(40758558) Short blood count panel - Blood
14
63
3.23
2.47
12.5
5.8
—
—
—
0
0
(40761535) Cells panel - Urine sediment
5
9
6.37
2.30
7.4
3.3
—
—
—
0
0
(3033658) Prothrombin time (PT) actual/Normal
11
47
3.08
2.06
2.3
2.2
%
82.2
93.6
1.27
11
47
(3003458) Phosphate [Moles/volume] in Serum or Plasma
7
24
3.46
1.85
5.7
7.5
mmol/l
1.2
1.2
—
7
24
(36304419) Bacteria [Presence] in Urine
12
59
2.69
1.72
3.0
2.2
—
—
—
0
0
(3044889) 12 lead EKG panel
18
110
2.52
1.65
2.4
2.6
—
—
—
0
0
(3000991) Gas panel - Venous blood
6
21
3.29
1.59
21.7
3.0
—
—
—
0
0
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
26
199
2.89
1.54
15.3
8.0
ml/min/173m2
105.2
101.1
0.35
19
150
(3024354) Oxygen [Partial pressure] in Venous blood
6
23
2.98
1.44
10.5
2.1
kpa
5.5
5.8
—
6
23
(3013512) EKG study
8
36
2.64
1.37
1.9
2.7
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
13
74
2.30
1.33
5.8
2.4
—
—
—
0
0
(3012544) pH of Venous blood
6
25
2.72
1.31
10.5
2.6
—
—
—
0
0
(3021447) Carbon dioxide [Partial pressure] in Venous blood
6
25
2.72
1.31
10.5
2.4
kpa
6.5
5.7
—
6
25
(3023368) Bacteria identified in Blood by Culture
8
39
2.41
1.27
9.6
3.4
—
—
—
0
0
(3007628) Bicarbonate [Moles/volume] standard in Venous blood
5
19
2.93
1.26
1.8
2.1
mmol/l
26.4
23.9
—
5
19
(3042936) Bacteria identified in Isolate by Culture
5
21
2.64
1.13
2.6
1.3
—
—
—
0
0
(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma
5
21
2.64
1.13
1.0
2.0
—
785.9
—
0
9
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
18
231
0.47
1.10
3.6
3.8
—
—
—
0
0
(3007853) Bacteria identified in Skin by Aerobe culture
6
27
2.51
1.00
1.3
1.3
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
8
45
2.04
0.93
3.6
1.9
—
—
—
0
0
(3009508) Creatinine [Moles/volume] in Urine
10
58
2.07
0.93
5.3
2.5
mmol/l
7.2
8.4
—
10
49
(3044640) Blood type and Crossmatch panel - Blood
10
60
1.98
0.84
4.0
1.9
—
—
—
0
0
(3002032) Base excess in Venous blood by calculation
5
24
2.28
0.78
12.4
2.5
mmol/l
3.8
1.4
—
5
14
(42870588) Differential panel, method unspecified - Blood
12
79
1.85
0.77
8.3
4.9
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
10
64
1.83
0.69
4.5
2.8
—
—
—
0
0
(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma
8
53
1.68
0.65
4.6
2.4
u/l
50.3
53.5
—
8
48
(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
0
20
0.00
0.63
0.0
1.5
—
—
—
0
0
(3002256) Pathology report gross observation
0
20
0.00
0.63
0.0
1.4
—
—
—
0
0
(3022145) Colonoscopy Study observation
0
20
0.00
0.63
0.0
1.6
—
—
—
0
0
(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum
0
21
0.00
0.62
0.0
1.8
—
214.1
—
0
8
(3037467) Urinalysis macro (dipstick) panel - Urine
19
155
1.58
0.51
4.6
3.8
—
—
—
0
0
(3011288) Drugs identified in Urine by Screen method
5
32
1.67
0.45
2.2
1.7
—
—
—
0
0
(3021879) Hepatitis B virus core Ab [Presence] in Serum
5
33
1.61
0.44
1.4
1.8
—
—
—
0
0
(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma
0
16
0.00
0.42
0.0
1.4
—
—
—
0
0
(3003327) Ova and parasites identified in Stool by Light microscopy
0
17
0.00
0.42
0.0
1.4
—
—
—
0
0
(3018677) aPTT in Platelet poor plasma by Coagulation assay
0
18
0.00
0.41
0.0
1.6
—
29.5
—
0
18
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
5
36
1.46
0.40
3.4
1.8
—
—
—
0
0
(3006504) Eosinophils/100 leukocytes in Blood
15
121
1.46
0.39
9.5
5.0
%
2.6
2.8
0.14
15
116
(3011397) Hemoglobin [Presence] in Urine by Test strip
6
43
1.49
0.38
8.8
3.1
—
—
—
0
0
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
11
88
1.39
0.27
1.9
1.8
—
—
—
0
0
(3002385) Erythrocyte distribution width [Ratio]
24
220
1.40
0.27
20.8
9.4
%
13.4
13.2
0.32
24
215
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
7
90
0.71
0.27
2.3
1.9
—
—
—
0
0
(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid
0
11
0.00
0.22
0.0
1.0
—
—
—
0
0
(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
0
10
0.00
0.22
0.0
1.2
—
—
—
0
0
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
12
101
1.31
0.21
9.8
3.8
—
—
—
0
0
(3016888) Borrelia burgdorferi IgG Ab [Units/volume] in Serum
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
5
67
0.70
0.19
1.8
1.9
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
11
93
1.28
0.17
2.5
2.4
—
—
—
0
0
(3001122) Ferritin [Mass/volume] in Serum or Plasma
12
105
1.23
0.14
2.3
2.5
ug/l
40.8
58.1
1.01
12
99
(3017143) Hepatitis C virus Ab [Presence] in Serum
6
56
1.09
0.09
1.8
1.8
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
6
69
0.84
0.08
3.5
2.5
—
—
—
0
0
(3019832) Treponema pallidum Ab [Presence] in Serum
7
82
0.81
0.08
1.4
1.8
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
10
90
1.16
0.06
1.4
1.8
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
10
97
1.05
0.00
2.9
2.7
—
—
—
0
0
(46235355) HIV 1 and 2 tests - Meaningful Use set
11
113
0.96
0.00
2.1
2.3
—
—
—
0
0
(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
5
57
0.85
0.00
1.8
1.4
—
—
—
0
0
(3036489) Thrombin time
0
7
0.00
0.00
0.0
1.3
—
19.9
—
0
7
(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3019150) Specific gravity of Urine by Refractometry
6
61
0.98
0.00
9.0
2.2
—
1.0
—
0
8
(3007566) Smooth muscle Ab [Titer] in Serum
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(40765089) Chromosome analysis panel - Blood by G-banded
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3034770) Mitochondria Ab [Titer] in Serum
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(4268621)
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(3047007) Chlamydophila sp Ab [Presence] in Serum
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3004588) Protein electrophoresis panel - Serum or Plasma
0
6
0.00
0.00
0.0
12.3
—
—
—
0
0
(3010726) Horse dander IgE Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
8
85
0.92
0.00
8.1
2.8
—
—
—
0
0
(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(40761511) CBC panel - Blood by Automated count
26
260
1.00
0.00
26.6
7.5
—
—
—
0
0
(3016251) Hemoglobin.gastrointestinal [Presence] in Stool
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3015736) pH of Urine
9
90
1.00
0.00
6.8
2.4
—
—
—
0
0
(40768793) Breast Pathology biopsy report
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3023150) Myeloperoxidase Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3037756) Immunofixation for Serum or Plasma
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
6
61
0.98
0.00
2.7
2.1
—
—
—
0
0
(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
1.3
—
28.7
—
0
7
(3025130) Human papilloma virus identified in Specimen
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
0
8
0.00
0.00
0.0
1.1
—
98.1
—
0
8
(3038177) Helicobacter pylori Ab [Presence] in Serum
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint Q17_FETAL_ALCOHOL_SYNDR_DYSMORPHIC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have Q17_FETAL_ALCOHOL_SYNDR_DYSMORPHIC.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

Index endpoint: Q17_FETAL_ALCOHOL_SYNDR_DYSMORPHIC – Fetal alcohol syndrome (dysmorphic)

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data